Floatz logo

Carboplatin

Childhood Neoplasm

Seoul National University HospitalSmall moleculePhase 2/3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Childhood Neoplasm cohort.

Asset / SponsorPhaseRating
Etoposide
City of Hope Medical Center
Phase 2/3BBB
Nivestim
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2/3BBB
Melphalan
City of Hope Medical Center
Phase 2/3BBB
Busulfanum
City of Hope Medical Center
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaActive
A
Indicative · Phase 4
80 / 100
View asset →
primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →
non-small cell squamous lung carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →